 |
 |
 |
 |
 |
 |
 |
 |
-
BROWSE TOPICS IN CLINICAL MANAGEMENT:
Antiretroviral Therapy- Complications of HIV/HAART
- Research & Development
- Clinical Trials
- Quality of Life & Patient Care
Antiretroviral Therapy
NNRTIs in Development
- A Clinical Overview of Capravirine (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health - Two NNRTIs in Early Development Show Promising Results (August 7, 2008)
From Project Inform - TMC278 (Rilpivirine) Efficacy, Toxicity and Pharmacokinetics (July 24, 2007)
In The 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO - An Alternative NNRTI, TMC278, Progresses in Development (February 28, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - NNRTIs in Development (March 30, 2006)
An overview from Edwin DeJesus, M.D.
From The Body - BILR 355 BS, a Second-Generation NNRTI, Shows Activity Against Most Common NNRTI Mutations (December 17, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - GW695634 Demonstrates Potent Activity in 7-Day Monotherapy Study in an NNRTI Treatment-Experienced Population (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment - Pfizer Discontinues Development of Capravirine, for HIV/AIDS (July 1, 2005)
From Pfizer, Inc. - Early Pre-Clinical Development of GW8248 Promising (September 14, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
  |
  |